# GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer

> **NCT06994507** · PHASE3 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 352 (estimated)

## Conditions studied

- Chemotherapy-induced Peripheral Neuropathy (CIPN)

## Interventions

- **DRUG:** GM1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06994507
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2026-09
- **Final completion:** 2027-06
- **Target enrollment:** 352 (ESTIMATED)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06994507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06994507, "GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06994507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*